List of Excipients in Branded Drug SELEXIPAG

Generic Drugs Containing SELEXIPAG

Company	Ingredient	NDC	Excipient
Zydus Pharmaceuticals (USA) Inc	selexipag	70710-1551	CARNAUBA WAX
Zydus Pharmaceuticals (USA) Inc	selexipag	70710-1551	CELLULOSE, MICROCRYSTALLINE
Zydus Pharmaceuticals (USA) Inc	selexipag	70710-1551	FERRIC OXIDE RED
Zydus Pharmaceuticals (USA) Inc	selexipag	70710-1551	FERRIC OXIDE YELLOW
Zydus Pharmaceuticals (USA) Inc	selexipag	70710-1551	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in SELEXIPAG?

# Of NDCs	Excipient
2	CARNAUBA WAX
2	CELLULOSE, MICROCRYSTALLINE
2	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW
2	HYDROXYPROPYL CELLULOSE

# Selexipag Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Selexipag is a small-molecule, twice-daily oral therapy for pulmonary arterial hypertension marketed by Johnson & Johnson under the brand Uptravi. Its commercial formulation uses conventional tablet excipients, creating opportunities in generic development, excipient sourcing, formulation optimization, and differentiated oral delivery. The strongest near-term opportunities are cost-efficient direct-compression platforms, low-risk excipient substitution, stability improvements, and manufacturing processes that support bioequivalence without relying on new clinical claims.

What is the commercial formulation of selexipag?

Uptravi is supplied as immediate-release film-coated tablets in multiple strengths. The product is administered orally twice daily, with or without food, according to the FDA prescribing information.[1]

What excipients are used in Uptravi tablets?

The listed inactive ingredients include standard tablet diluents, disintegrants, binders, lubricants, and film-coating components. The FDA label identifies the core excipient system as including:

Functional role	Representative Uptravi excipient
Diluent	Mannitol
Disintegrant or compression aid	Corn starch
Binder and disintegrant	Low-substituted hydroxypropyl cellulose
Film former	Hypromellose
Lubricant	Magnesium stearate
Coating and color system	Titanium dioxide, talc, and iron oxides, depending on strength

Exact quantities and manufacturing parameters are not generally disclosed in the commercial label.[1] A generic developer must therefore establish equivalence through formulation development, comparative dissolution, stability testing, and pharmacokinetic bioequivalence studies.

The formulation does not depend on a novel lipid carrier, injectable depot, osmotic system, or biologic stabilizer. That limits the value of highly specialized excipients but favors scalable suppliers of pharmaceutical-grade mannitol, cellulose derivatives, starch, coating polymers, and lubricants.

What formulation characteristics create excipient opportunities for selexipag?

The principal formulation opportunity is control of dissolution and manufacturability rather than creation of a new therapeutic delivery system.

Solubility and dissolution control

Selexipag is a low-dose active pharmaceutical ingredient. Low-dose products can be sensitive to blend uniformity, segregation, particle-size distribution, and tablet weight variation. Excipient selection should support:

• Uniform API distribution at low drug loading.
• Rapid and reproducible disintegration.
• Consistent dissolution across commercial strengths.
• Low sensitivity to magnesium stearate over-lubrication.
• Adequate tablet hardness without delaying release.
• Stability under humidity and temperature stress.

Mannitol can provide good mouthfeel and compactability. Low-substituted hydroxypropyl cellulose can support both tablet strength and disintegration. Alternative excipients should be assessed by function, not by nominal chemical similarity.

Potential replacement systems include:

Current or likely function	Candidate commercial alternatives	Primary development issue
Mannitol diluent	Microcrystalline cellulose, lactose, spray-dried mannitol, dibasic calcium phosphate	Density, compactability, dissolution
Corn starch	Crospovidone, croscarmellose sodium, pregelatinized starch	Disintegration profile and moisture sensitivity
Low-substituted HPC	Crospovidone, sodium starch glycolate, microcrystalline cellulose	Tablet strength versus release rate
Hypromellose coating	Polyvinyl alcohol, HPMC-based premix, hypromellose-phthalate where justified	Processability, color matching, regulatory qualification
Magnesium stearate	Sodium stearyl fumarate, stearic acid	Lubrication efficiency and dissolution impact

The most commercially realistic products will usually retain a familiar excipient architecture while changing grade, particle size, supplier, or manufacturing process.

How can generic manufacturers design a selexipag excipient strategy?

A generic strategy should begin with a formulation fingerprint of the reference product.

Recommended development sequence

1. Characterize reference tablets across strengths for weight, hardness, friability, disintegration, dissolution, assay, content uniformity, and impurity profile.
2. Map API particle size, morphology, polymorphism, and bulk density.
3. Identify whether direct compression, dry granulation, or wet granulation best controls blend uniformity.
4. Screen excipient grades rather than only excipient identities.
5. Establish discriminatory dissolution methods using multiple media and agitation conditions.
6. Confirm that the formulation remains bioequivalent after scale-up and site transfer.
7. Lock critical material attributes and critical process parameters before commercial validation.

Direct compression offers the lowest process complexity if the API and excipient blend have adequate flow and compressibility. Dry granulation may improve uniformity and reduce segregation. Wet granulation can improve content uniformity but introduces water and heat exposure, which may increase degradation risk or complicate scale-up.

Which excipient properties matter most?

For selexipag, the key attributes are likely to include:

• Particle-size distribution of the API and diluent.
• Surface area and porosity of the disintegrant.
• Moisture content of starch and cellulose excipients.
• Bulk density and flowability.
• Lubricant surface area and mixing time.
• Coating suspension viscosity and pigment dispersion.
• Container-closure protection against moisture.

A supplier that offers narrow lot-to-lot variability, global regulatory documentation, and multiple compendial grades can capture more value than a supplier offering only a lower unit price.

What commercial opportunities exist for excipient suppliers?

Pharmaceutical-grade mannitol

Mannitol is a high-volume excipient with established regulatory acceptance. Opportunities include:

• Direct-compression grades optimized for low-dose tablets.
• Low-bioburden and low-endotoxin grades.
• Consistent particle-size distributions for blend uniformity.
• Dual-source supply from geographically separated facilities.
• Technical support for scale-up and tablet tooling.

Because selexipag tablets are manufactured in several strengths, a single excipient platform that supports multiple tablet weights has commercial value.

Cellulose-based excipients

Low-substituted HPC and hypromellose suppliers can compete through:

• Controlled substitution levels.
• Improved compressibility.
• Low-moisture grades.
• Reduced variability in hydration and swelling.
• Documentation supporting global abbreviated applications.

Cellulose excipients can also support reformulation programs if a generic sponsor seeks to avoid a specific reference-product composition while maintaining immediate release.

Coating systems

Film-coating suppliers can provide preformulated systems that reduce development time. Commercial opportunities include:

• Color-matched coatings for each strength.
• Lower-temperature coating systems.
• Reduced coating weight.
• Improved moisture barrier performance.
• Pigment systems with simplified global regulatory status.

Coating is unlikely to provide a major therapeutic differentiation, but it can reduce manufacturing cost and improve product identification.

What patents protect selexipag formulations and excipients?

Selexipag is protected by a combination of small-molecule, formulation, manufacturing, and method-of-use patent rights. The relevant legal distinction is between:

• Composition-of-matter claims covering selexipag or related chemical entities.
• Pharmaceutical-composition claims covering selexipag with excipients.
• Method-of-use claims covering treatment of pulmonary arterial hypertension.
• Manufacturing claims covering synthesis, intermediates, or purification.
• Crystalline, polymorph, salt, or particle-property claims, where applicable.

An excipient substitution does not automatically avoid patent infringement. A formulation patent may claim the active ingredient with broad classes of diluents, binders, disintegrants, or release agents. Conversely, a patent that claims only a narrow excipient combination may be avoided through a carefully designed alternative formulation.

How strong is the formulation patent estate?

The practical strength of a selexipag formulation patent depends on claim breadth, prosecution history, written-description support, enablement, and the existence of non-infringing formulations. Broad claims covering any tablet containing selexipag and a conventional excipient are vulnerable to validity and written-description challenges if the specification does not support the full scope.

Narrow claims can be easier to defend but may be easier for a generic sponsor to design around. The highest-risk claims for generic developers are those that combine:

• Selexipag at a defined dose range.
• A specific disintegrant or cellulose derivative.
• A defined dissolution profile.
• A manufacturing process linked to content uniformity or stability.
• A method of treating pulmonary arterial hypertension.

Current U.S. patent numbers, expiration dates, and Orange Book listing status must be assessed from the live FDA Orange Book and the applicable patent-family records because listed patents and pediatric extensions can change the effective timing analysis.[2]

When does selexipag lose regulatory exclusivity?

Uptravi received FDA approval on December 21, 2015. It was approved as an orphan drug for pulmonary arterial hypertension and received new chemical entity exclusivity under the FDA framework.[3]

Regulatory right	General timing
FDA approval	December 21, 2015
Five-year NCE exclusivity	Generally expired in December 2020
Orphan-drug exclusivity	Generally extends seven years from approval, subject to the statutory indication
Patent protection	Depends on listed U.S. patents, term adjustments, and extensions
Generic pathway	ANDA with Paragraph IV or Paragraph III certification, depending on live patents

Regulatory exclusivity is separate from patent protection. The end of NCE or orphan exclusivity does not establish a generic launch date if unexpired patents remain listed or enforceable.

What Paragraph IV challenges and generic entry risks exist?

A generic sponsor seeking approval before patent expiry may submit a Paragraph IV certification stating that a listed patent is invalid, unenforceable, or will not be infringed. The patent holder can file an infringement action, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[4]

The main generic entry scenarios are:

Scenario	Commercial consequence
Paragraph III certification	Approval waits until the relevant patent expires
Paragraph IV certification with no litigation	Potential approval after FDA review and statutory conditions
Paragraph IV certification followed by litigation	Approval may be delayed by the 30-month stay or court outcome
Authorized generic	Price pressure can begin without a separate ANDA launch
Formulation design-around	Reduces infringement exposure but may increase development cost

The most defensible generic program would use a simple immediate-release tablet with a non-infringing excipient composition and a dissolution profile comparable to the reference product. A reformulation that changes release behavior could create additional clinical and regulatory requirements.

What FDA regulatory status applies to selexipag generics?

Selexipag is a small-molecule drug, so the relevant pathway is an ANDA rather than a biosimilar application. FDA review will focus on pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and patent certifications.[5]

Key regulatory considerations include:

• Same active ingredient and dosage form.
• Same strength options or approved strength strategy.
• Immediate-release performance.
• Adequate content uniformity at low dose.
• Comparative dissolution.
• Stability data using the proposed commercial package.
• Inactive-ingredient justification where required.
• Compliance with current good manufacturing practices.

There is no biosimilar pathway for selexipag. Biosimilar competition is therefore irrelevant to the product’s direct exclusivity analysis.

What formulation patents could support lifecycle management?

A lifecycle program could pursue several technical directions, although each would require a distinct regulatory and commercial case.

Pediatric or swallowability formulation

A dispersible, mini-tablet, or oral-suspension formulation could address patients who cannot swallow conventional tablets. This would require attention to:

• Taste masking.
• Suspension uniformity.
• Dose flexibility.
• Chemical and microbiological stability.
• Device compatibility.
• Administration through feeding tubes, if claimed.

Modified-release delivery

A once-daily formulation could have commercial value because Uptravi is administered twice daily. The technical challenge is maintaining exposure to selexipag and its active metabolite while avoiding peak-related tolerability problems. Such a product would likely require new pharmacokinetic and clinical evidence, making it a higher-cost opportunity than a conventional generic.

Fixed-dose combinations

A combination with another pulmonary arterial hypertension therapy could reduce pill burden. Potential partners include agents used in combination treatment, such as endothelin-receptor antagonists or phosphodiesterase-5 inhibitors. The regulatory burden would include interaction studies, dose selection, combination safety, and evidence that the fixed combination provides a meaningful clinical or adherence advantage.

Improved stability and packaging

A formulation or package that reduces moisture uptake, impurity formation, or tablet degradation could produce a commercially useful product without changing the active drug. Relevant patent claims could cover:

• Desiccant-containing packaging.
• High-barrier blister materials.
• Specific moisture limits.
• Stabilizing excipient combinations.
• Manufacturing under controlled humidity.

How does selexipag compare with competing pulmonary arterial hypertension products?

Selexipag competes with oral, inhaled, and parenteral pulmonary arterial hypertension therapies. Its closest commercial comparison is with other oral agents used in combination regimens.

Product category	Formulation opportunity	Excipient opportunity
Selexipag	Immediate-release tablet and potential modified-release products	Low-dose uniformity, dissolution, coating, stability
Endothelin-receptor antagonists	Tablets and combination products	Solubility, tablet size, fixed-dose combinations
PDE-5 inhibitors	Tablets and oral suspensions	Taste masking, dispersibility, pediatric dosing
Prostacyclin analogues	Inhaled, injectable, or oral products	Device compatibility, sterile excipients, pulmonary delivery

Selexipag’s commercial differentiation rests on its oral prostacyclin-pathway mechanism and use in long-term combination therapy. Excipient suppliers can participate in this market through manufacturing efficiency rather than through a single proprietary excipient.

What revenue exposure does Uptravi create?

Uptravi is a material pulmonary arterial hypertension product for Johnson & Johnson. Annual sales have been approximately $1 billion or more in recent reporting periods, making eventual generic entry commercially significant.[6]

Revenue erosion would likely occur in stages:

1. Limited erosion after the first generic launch.
2. Faster price decline as multiple ANDA holders enter.
3. Greater pressure if an authorized generic is introduced.
4. Continued branded demand for established physicians, combination use, and supply reliability.
5. Potential retention through new formulations or indication-specific lifecycle products.

Excipient suppliers should view the opportunity as a portfolio market. The addressable value includes reference-product supply, generic launches, contract manufacturing, reformulation programs, and global dual-sourcing projects.

What manufacturing and geographic barriers affect selexipag excipient supply?

The primary barriers are operational rather than chemical. Suppliers must support:

• FDA, EMA, and other major-market quality systems.
• Multiple compendial standards.
• Change-control documentation.
• Extractables and leachables data for packaging systems.
• Nitrosamine and elemental-impurity assessments where relevant.
• Reliable supply across North America, Europe, and Asia.
• Qualified alternate manufacturing sites.

Excipient changes after approval can require regulatory notification or approval depending on the change and jurisdiction. A supplier with prequalified grades, robust documentation, and validated scale-up support can reduce switching friction for generic manufacturers.

Key Takeaways

• Selexipag is marketed as the twice-daily oral tablet Uptravi for pulmonary arterial hypertension.
• The reference formulation uses conventional excipients, including mannitol, starch, cellulose derivatives, hypromellose, magnesium stearate, and film-coating components.
• The strongest generic opportunity is a bioequivalent immediate-release tablet using a non-infringing excipient composition.
• Excipient differentiation should focus on low-dose content uniformity, dissolution control, tablet robustness, moisture protection, and supply reliability.
• Modified-release, pediatric, dispersible, and fixed-dose combination products offer higher potential value but require greater regulatory investment.
• Selexipag has no biosimilar risk because it is a small molecule.
• Patent analysis must separate composition, formulation, method-of-use, and manufacturing claims.
• Uptravi’s commercial exposure is significant because annual sales have reached approximately $1 billion or more.
• The best supplier opportunities are pharmaceutical-grade mannitol, cellulose derivatives, disintegrants, coating systems, and high-barrier packaging.

FAQs

Can mannitol be replaced in a selexipag generic tablet?

Yes. Mannitol can potentially be replaced with microcrystalline cellulose, lactose, spray-dried mannitol, or another suitable diluent, subject to content uniformity, dissolution, stability, manufacturability, and regulatory requirements.

Is selexipag suitable for a taste-masked oral suspension?

Potentially, but taste masking, dose uniformity, suspension stability, chemical stability, and administration-device compatibility would require dedicated development and regulatory support.

Does changing an excipient avoid a selexipag patent?

Not necessarily. A patent may claim broad excipient classes, a defined composition, a dissolution profile, or a manufacturing process. Freedom to operate requires claim-by-claim analysis.

Are selexipag tablets likely to require a specialized coating polymer?

No specialized polymer is inherently required by the commercial product. Conventional hypromellose-based coating systems or suitable alternatives can be considered, subject to color, stability, process, and regulatory performance.

What is the highest-value lifecycle opportunity for selexipag?

A once-daily or patient-friendly oral formulation has the greatest potential commercial differentiation, but it also carries substantially higher pharmacokinetic, clinical, manufacturing, and patent-development costs than a conventional generic tablet.

References

1. U.S. Food and Drug Administration. (2024). Uptravi (selexipag) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). FDA approves new treatment for pulmonary arterial hypertension.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant or non-recombinant origin.
6. Johnson & Johnson. (2024). Annual report for fiscal year 2023.